Skip to content
Head to head

Harrow vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: HROW · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

HROW -32.6%TAK +28.0%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
HROWTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price30.6218.37
Change today+0.89%+1.49%
1-year return-26.9%+29.2%
Market cap$1.15B$58.68B
52-week range28.54 – 54.8512.77 – 19.10
Valuation
P/E (TTM)-30.93-55.67
P/E percentile, own 5-yr range47th4th
P/B75.601.23
Dividend yield0.00%3.26%
Profitability & growth
EPS (TTM)-0.14-0.31
Net profit (TTM)$-5.25M$-977.54M
Revenue (TTM)$275.59M$4.62T
Revenue growth (YoY)+10.9%+10.2%
Gross margin73.3%65.5%
Operating margin-1.0%10.4%
Net margin-13.5%-3.5%
Free cash flow (TTM)$-13.08M$626.68B
Ownership & sentiment
Institutional ownership58.6%51.5%
Insider activity (12mo)32 buy / 18 sell22 buy / 28 sell
Short interest (% of float)20.0%0.1%
Analyst consensus100% buy (8)100% buy (1)
Analyst price target$64 (+110%)$43 (+134%)
StockVane view
StockVane Quant RatingD (42)C (70)
Company
Employees37347,029
Founded20061781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.